{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 9,
  "pageCount": 32,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "context",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/9",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.02,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Inherited from BlackThorn trial timeline",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "716c9bd5-d0be-4cf3-89d0-35074cafbe42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.42,
        "y": 0.7
      },
      "kind": "list",
      "text": "Neumora Amendments to Optimize Trial details",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fe77d8d-1602-473d-9955-c04849d994de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.02,
        "y": 0.7
      },
      "kind": "list",
      "text": "Initial Study Inclusion (pre-Neumora) details",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "431948e5-97c2-41b3-b9e6-ea1b4e7a0c42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.2,
        "x": 0.78,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Study Endpoints and Final Efficacy Population",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0be516fc-4a56-4839-bedf-865de7833683",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1) Patients with a baseline HAMD-17 total score that received at least one dose of study drug and had at least one post-baseline HAMD-17 assessment 2) Baseline HAMD-17 score ≥22",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5aa97d7-73ba-477d-8981-94ce3babb569",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.42,
        "y": 0.345
      },
      "kind": "table",
      "text": "Product Candidate MDD Severity Criteria table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7fcd452-9d82-4249-a0db-e224f2b5e11b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Navacaprant: Phase 2a Trial Design Amended by Neumora after Acquisition of BlackThorn",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65fd29a3-78da-470d-850c-2d2cd094d828",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.02,
        "y": 0.09
      },
      "kind": "title",
      "text": "Amendments included expanding enrollment criteria to allow patients with moderate-to-severe MDD",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc999372-c832-42f5-a298-4d3bc54446b3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "31ce5f5d-5317-4b36-b7ea-752eafa9b532",
      "evidence": "table/data: Product Candidate MDD Severity Criteria table",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "b86f5a0b-cb60-48b5-aa60-11d2f12c2b2d",
      "evidence": "Contrasts 'Inherited from BlackThorn' with 'Neumora Amendments to Optimize Trial'",
      "confidence": 0.95
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "ae418749-a82f-4297-ba0f-ee67621e0c10",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Complication",
      "beatSlug": "complication",
      "evidence": "Slides highlighting the limitations of current treatments and the unmet needs in brain disease treatment.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2bd7ba03-4d81-4e19-bd9c-4d10d02b1402",
      "evidence": "The complication slides highlighting current treatment limitations.",
      "position": 0,
      "objective": "What are the consequences of not addressing the unmet needs in brain disease treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}